Vancouver, British Columbia and Sacramento, California — December 31, 2025 — Leads & Copy — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced the results of its Annual General and Special Meeting, which was held on December 29, 2025.
Shareholders approved all company matters submitted for approval as outlined in the Notice of Meeting and Management Information Circular dated November 27, 2025. The proposals passed with the required majority of votes.
Key actions taken at the meeting included the election of five directors for the upcoming year, the reappointment of Dale Matheson Carr-Hilton LaBonte LLP as the company’s auditor, and an amendment to the company’s bylaws. The bylaw change reduces the quorum requirement from 20% to a minimum of 1% of the issued voting shares, while maintaining the requirement for majority approval on all decisions. This amendment addresses persistent challenges faced by public companies, such as mail delays and disruptions, and delays experienced by shareholders using self-managed trading platforms when receiving voting packages.
The company expressed gratitude to all shareholders for their participation and continued support.
Izotropic Corporation is focused on commercializing innovative, emerging technologies and imaging-based products for more accurate screening, diagnosis, and treatment of breast cancers.
Robert Thast, Interim Chief Executive Officer, can be reached at 1-604-220-5031 or 1-833-IZOCORP ext. 1, or via email at bthast@izocorp.com. General and corporate inquiries can be directed to 1-604-825-4778 or 1-833-IZOCORP ext. 3, or via email at info@izocorp.com.
Source: Izotropic Corporation
